GSDME and cancer: Studies have used hypomethylating agents such as decitabine (DAC) (Fan et al., 2019) or 5-aza-2′-deoxycytidine (5-Aza-CdR) (Kim et al., 2008b) to restore the transcription of the GSDME gene and reinstate the sensitivity of various cancer cells, including GC cells, to chemotherapy (Akino et al., 2007).